Subscribe to RSS
DOI: 10.1055/s-0039-3399644
Mistletoe in adjuvant cancer treatment of companion animals
Publication History
Publication Date:
20 December 2019 (online)
Cancer diseases are frequent in veterinary practice and overall there is a 23% – 45 % risk for dogs to die from cancer. Oral malignant melanoma (OMM) as well as canine mammary tumor (CMT) show high malignancy and adjuvant treatment is needed. The aim of both controlled trials was to explore if viscum album L. extract (VAE) therapy might be a potential treatment of OMM and CTM. In OMM the adjuvant VAE treatment showed a significant longer median survival time (MST) with 236 days compared to the control (radiation only) with 49 days (p = 0,0047). Adjuvant VAE treatment in CMT showed not significant differences in MST compared to the control group (surgery only). A tendency (p= 0,7) of decrease in tumor-related death risk (TRDR) to 25% (HR 0.251, 95% CI 0.056–1.122; p = 0.07) was observed for the treatment group, with stable Quality of life during entire treatment.
-
References
- 1 Bodungen Uv, Ruess K, Reif M, Biegel U. Combination therapy with radiation and adjuvant mistletoe extract (Viscum album L.) for the treatment of oral malignant melanoma in dogs: a retrospective study. Complementary Med Res 2017; 24: 358-363 .
- 2 Biegel U, Stratmann N, Knauf Y, Ruess K, Reif M, Wehrend A. Postsurgical adjuvant treatment with mistletoe extract (Viscum album ssp. album) in canine mammary tumors. Complementary Med Res 2017; 24: 349-357 .